 The stock price of Sangamo Therapeutics, a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, in vivo genome editing, and in vivo genome regulation, has seen a 17 drop over the last ten trading days, while its down 11. 